Study of Azacitidine in Adult Taiwanese Subjects With Higher-Risk Myelodysplastic Syndromes (MDS)

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 1, 2010

Primary Completion Date

May 1, 2013

Study Completion Date

May 1, 2013

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Azacitidine

Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.

Trial Locations (11)

404

China Medical University Hospital, Taichung

500

Changhua Christian Hospital, Changhua

613

Chiayi Chang Gung Memorial Hospital, Chiayi City

704

National Cheng Kung University Hospital, Tainan City

807

Kaohsiung Medical Hospital University, Kaohsiung City

833

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

970

Buddhist Tzu Chi General Hospital-Hualien Tzu Chi Medical Center, Hualien City

10002

National Taiwan University Hospital, Taipei

11217

Taipei Veterans General Hospital, Taipei

11490

Tri-Service General Hospital, Taipei

23561

Shuang-ho Hospital, New Taipei City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY